Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.

Hibbitts E, Chi YY, Hawkins DS, Barr FG, Bradley JA, Dasgupta R, Meyer WH, Rodeberg DA, Rudzinski ER, Spunt SL, Skapek SX, Wolden SL, Arndt CAS.

Cancer Med. 2019 Oct;8(14):6437-6448. doi: 10.1002/cam4.2504. Epub 2019 Aug 27.

2.

Rhabdomyosarcoma.

Skapek SX, Ferrari A, Gupta AA, Lupo PJ, Butler E, Shipley J, Barr FG, Hawkins DS.

Nat Rev Dis Primers. 2019 Jan 7;5(1):1. doi: 10.1038/s41572-018-0051-2. Review.

PMID:
30617281
3.

Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma.

Sun W, Chatterjee B, Shern JF, Patidar R, Song Y, Wang Y, Walker RL, Pawel BR, Linardic CM, Houghton P, Hewitt SM, Edelman DC, Khan J, Meltzer PS, Barr FG.

Int J Cancer. 2019 Jun 1;144(11):2707-2717. doi: 10.1002/ijc.32006. Epub 2019 Jan 15.

PMID:
30565669
4.

The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma.

Bharathy N, Berlow NE, Wang E, Abraham J, Settelmeyer TP, Hooper JE, Svalina MN, Ishikawa Y, Zientek K, Bajwa Z, Goros MW, Hernandez BS, Wolff JE, Rudek MA, Xu L, Anders NM, Pal R, Harrold AP, Davies AM, Ashok A, Bushby D, Mancini M, Noakes C, Goodwin NC, Ordentlich P, Keck J, Hawkins DS, Rudzinski ER, Chatterjee B, Bächinger HP, Barr FG, Liddle J, Garcia BA, Mansoor A, Perkins TJ, Vakoc CR, Michalek JE, Keller C.

Sci Signal. 2018 Nov 20;11(557). pii: eaau7632. doi: 10.1126/scisignal.aau7632.

5.

Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma.

Nguyen TH, Barr FG.

Molecules. 2018 Oct 28;23(11). pii: E2798. doi: 10.3390/molecules23112798. Review.

6.

The expression and function of PAX3 in development and disease.

Boudjadi S, Chatterjee B, Sun W, Vemu P, Barr FG.

Gene. 2018 Aug 5;666:145-157. doi: 10.1016/j.gene.2018.04.087. Epub 2018 May 4. Review.

7.

Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.

Rudzinski ER, Anderson JR, Chi YY, Gastier-Foster JM, Astbury C, Barr FG, Skapek SX, Hawkins DS, Weigel BJ, Pappo A, Meyer WH, Arnold MA, Teot LA, Parham DM.

Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26645. Epub 2017 May 18.

8.

PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.

Gryder BE, Yohe ME, Chou HC, Zhang X, Marques J, Wachtel M, Schaefer B, Sen N, Song Y, Gualtieri A, Pomella S, Rota R, Cleveland A, Wen X, Sindiri S, Wei JS, Barr FG, Das S, Andresson T, Guha R, Lal-Nag M, Ferrer M, Shern JF, Zhao K, Thomas CJ, Khan J.

Cancer Discov. 2017 Aug;7(8):884-899. doi: 10.1158/2159-8290.CD-16-1297. Epub 2017 Apr 26.

9.

PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma.

Pandey PR, Chatterjee B, Olanich ME, Khan J, Miettinen MM, Hewitt SM, Barr FG.

J Pathol. 2017 Apr;241(5):626-637. doi: 10.1002/path.4867. Epub 2017 Mar 1.

10.

Molecular diagnostics in the management of rhabdomyosarcoma.

Arnold MA, Barr FG.

Expert Rev Mol Diagn. 2017 Feb;17(2):189-194. doi: 10.1080/14737159.2017.1275965. Epub 2017 Jan 6. Review.

11.

Fusion transcriptome profiling provides insights into alveolar rhabdomyosarcoma.

Xie Z, Babiceanu M, Kumar S, Jia Y, Qin F, Barr FG, Li H.

Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13126-13131. Epub 2016 Oct 31.

12.

Fusion genes in solid tumors: the possibilities and the pitfalls.

Barr FG.

Expert Rev Mol Diagn. 2016 Sep;16(9):921-3. doi: 10.1080/14737159.2016.1220835. Epub 2016 Aug 23. No abstract available.

13.

Human rhabdomyosarcoma cells express functional pituitary and gonadal sex hormone receptors: Therapeutic implications.

Poniewierska-Baran A, Schneider G, Sun W, Abdelbaset-Ismail A, Barr FG, Ratajczak MZ.

Int J Oncol. 2016 May;48(5):1815-24. doi: 10.3892/ijo.2016.3439. Epub 2016 Mar 11.

14.

Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group.

Arnold MA, Anderson JR, Gastier-Foster JM, Barr FG, Skapek SX, Hawkins DS, Raney RB Jr, Parham DM, Teot LA, Rudzinski ER, Walterhouse DO.

Pediatr Blood Cancer. 2016 Apr;63(4):634-9. doi: 10.1002/pbc.25862. Epub 2016 Jan 12.

15.

Human rhabdomyosarcoma cells express functional erythropoietin receptor: Potential therapeutic implications.

Poniewierska-Baran A, Suszynska M, Sun W, Abdelbaset-Ismail A, Schneider G, Barr FG, Ratajczak MZ.

Int J Oncol. 2015 Nov;47(5):1989-97. doi: 10.3892/ijo.2015.3184. Epub 2015 Sep 24.

16.

Distinct methylation profiles characterize fusion-positive and fusion-negative rhabdomyosarcoma.

Sun W, Chatterjee B, Wang Y, Stevenson HS, Edelman DC, Meltzer PS, Barr FG.

Mod Pathol. 2015 Sep;28(9):1214-24. doi: 10.1038/modpathol.2015.82. Epub 2015 Jul 31.

17.

CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.

Olanich ME, Sun W, Hewitt SM, Abdullaev Z, Pack SD, Barr FG.

Clin Cancer Res. 2015 Nov 1;21(21):4947-59. doi: 10.1158/1078-0432.CCR-14-2955. Epub 2015 Mar 25.

18.

Clonality and evolutionary history of rhabdomyosarcoma.

Chen L, Shern JF, Wei JS, Yohe ME, Song YK, Hurd L, Liao H, Catchpoole D, Skapek SX, Barr FG, Hawkins DS, Khan J.

PLoS Genet. 2015 Mar 13;11(3):e1005075. doi: 10.1371/journal.pgen.1005075. eCollection 2015 Mar.

19.

Rhabdomyosarcoma: current challenges and their implications for developing therapies.

Hettmer S, Li Z, Billin AN, Barr FG, Cornelison DD, Ehrlich AR, Guttridge DC, Hayes-Jordan A, Helman LJ, Houghton PJ, Khan J, Langenau DM, Linardic CM, Pal R, Partridge TA, Pavlath GK, Rota R, Schäfer BW, Shipley J, Stillman B, Wexler LH, Wagers AJ, Keller C.

Cold Spring Harb Perspect Med. 2014 Nov 3;4(11):a025650. doi: 10.1101/cshperspect.a025650. Review.

20.

Malignant round cell tumor of bone with EWSR1-NFATC2 gene fusion.

Sadri N, Barroeta J, Pack SD, Abdullaev Z, Chatterjee B, Puthiyaveettil R, Brooks JS, Barr FG, Zhang PJ.

Virchows Arch. 2014 Aug;465(2):233-9. doi: 10.1007/s00428-014-1613-7. Epub 2014 Jul 4.

21.

A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.

Kohsaka S, Shukla N, Ameur N, Ito T, Ng CK, Wang L, Lim D, Marchetti A, Viale A, Pirun M, Socci ND, Qin LX, Sciot R, Bridge J, Singer S, Meyers P, Wexler LH, Barr FG, Dogan S, Fletcher JA, Reis-Filho JS, Ladanyi M.

Nat Genet. 2014 Jun;46(6):595-600. doi: 10.1038/ng.2969. Epub 2014 May 4.

22.

Myogenin, AP2β, NOS-1, and HMGA2 are surrogate markers of fusion status in rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children's oncology group.

Rudzinski ER, Anderson JR, Lyden ER, Bridge JA, Barr FG, Gastier-Foster JM, Bachmeyer K, Skapek SX, Hawkins DS, Teot LA, Parham DM.

Am J Surg Pathol. 2014 May;38(5):654-9. doi: 10.1097/PAS.0000000000000195.

23.

Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.

Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, Tolman C, Hurd L, Liao H, Zhang S, Bogen D, Brohl AS, Sindiri S, Catchpoole D, Badgett T, Getz G, Mora J, Anderson JR, Skapek SX, Barr FG, Meyerson M, Hawkins DS, Khan J.

Cancer Discov. 2014 Feb;4(2):216-31. doi: 10.1158/2159-8290.CD-13-0639. Epub 2014 Jan 23.

24.

The paternally imprinted DLK1-GTL2 locus is differentially methylated in embryonal and alveolar rhabdomyosarcomas.

Schneider G, Bowser MJ, Shin DM, Barr FG, Ratajczak MZ.

Int J Oncol. 2014 Jan;44(1):295-300. doi: 10.3892/ijo.2013.2153. Epub 2013 Oct 29.

25.

Classification of rhabdomyosarcoma and its molecular basis.

Parham DM, Barr FG.

Adv Anat Pathol. 2013 Nov;20(6):387-97. doi: 10.1097/PAP.0b013e3182a92d0d. Review.

26.

A novel algorithm for simplification of complex gene classifiers in cancer.

Wilson RA, Teng L, Bachmeyer KM, Bissonnette ML, Husain AN, Parham DM, Triche TJ, Wing MR, Gastier-Foster JM, Barr FG, Hawkins DS, Anderson JR, Skapek SX, Volchenboum SL.

Cancer Res. 2013 Sep 15;73(18):5625-32. doi: 10.1158/0008-5472.CAN-13-0324. Epub 2013 Aug 2.

27.

Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls.

Hinson AR, Jones R, Crose LE, Belyea BC, Barr FG, Linardic CM.

Front Oncol. 2013 Jul 17;3:183. doi: 10.3389/fonc.2013.00183. eCollection 2013.

28.

Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Rudzinski ER, Teot LA, Anderson JR, Moore J, Bridge JA, Barr FG, Gastier-Foster JM, Skapek SX, Hawkins DS, Parham DM.

Am J Clin Pathol. 2013 Jul;140(1):82-90. doi: 10.1309/AJCPA1WN7ARPCMKQ.

29.

PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.

Skapek SX, Anderson J, Barr FG, Bridge JA, Gastier-Foster JM, Parham DM, Rudzinski ER, Triche T, Hawkins DS.

Pediatr Blood Cancer. 2013 Sep;60(9):1411-7. doi: 10.1002/pbc.24532. Epub 2013 Mar 22.

30.

A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma.

Olanich ME, Barr FG.

Expert Opin Ther Targets. 2013 May;17(5):607-23. doi: 10.1517/14728222.2013.772136. Epub 2013 Feb 25. Review.

31.

RasGRF1 regulates proliferation and metastatic behavior of human alveolar rhabdomyosarcomas.

Tarnowski M, Schneider G, Amann G, Clark G, Houghton P, Barr FG, Kenner L, Ratajczak MZ, Kucia M.

Int J Oncol. 2012 Sep;41(3):995-1004. doi: 10.3892/ijo.2012.1536. Epub 2012 Jun 28.

32.

New Treatments for Rhabdomyosarcoma: the Importance of Target Practice.

Barr FG.

Clin Cancer Res. 2012 Feb 1;18(3):595-597. Epub 2011 Dec 13.

33.

TRIG on TRACK: educating pathology residents in genomic medicine.

Haspel RL, Atkinson JB, Barr FG, Kaul KL, Leonard DG, O'Daniel J, Rinder HM, Scott J, Sobel ME, Speights VO.

Per Med. 2012 May;9(3):287-293. doi: 10.2217/pme.12.6.

PMID:
29758790
34.

Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: a report from the Children's Oncology Group.

Duan F, Smith LM, Gustafson DM, Zhang C, Dunlevy MJ, Gastier-Foster JM, Barr FG.

Genes Chromosomes Cancer. 2012 Jul;51(7):662-74. doi: 10.1002/gcc.21953. Epub 2012 Mar 23.

35.

Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.

Shukla N, Ameur N, Yilmaz I, Nafa K, Lau CY, Marchetti A, Borsu L, Barr FG, Ladanyi M.

Clin Cancer Res. 2012 Feb 1;18(3):748-57. doi: 10.1158/1078-0432.CCR-11-2056. Epub 2011 Dec 5.

36.

Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: a report from the Children's Oncology Group.

Pressey JG, Anderson JR, Crossman DK, Lynch JC, Barr FG.

Pediatr Blood Cancer. 2011 Dec 1;57(6):930-8. doi: 10.1002/pbc.23174. Epub 2011 May 25.

37.

Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma.

Rubin BP, Nishijo K, Chen HI, Yi X, Schuetze DP, Pal R, Prajapati SI, Abraham J, Arenkiel BR, Chen QR, Davis S, McCleish AT, Capecchi MR, Michalek JE, Zarzabal LA, Khan J, Yu Z, Parham DM, Barr FG, Meltzer PS, Chen Y, Keller C.

Cancer Cell. 2011 Feb 15;19(2):177-91. doi: 10.1016/j.ccr.2010.12.023.

38.

Genomic and clinical analysis of amplification of the 13q31 chromosomal region in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group.

Reichek JL, Duan F, Smith LM, Gustafson DM, O'Connor RS, Zhang C, Dunlevy MJ, Gastier-Foster JM, Barr FG.

Clin Cancer Res. 2011 Mar 15;17(6):1463-73. doi: 10.1158/1078-0432.CCR-10-0091. Epub 2011 Jan 10.

39.

Fusion-negative alveolar rhabdomyosarcoma: modification of risk stratification is premature.

Anderson JR, Barr FG, Hawkins DS, Parham DM, Skapek SX, Triche TJ.

J Clin Oncol. 2010 Oct 10;28(29):e587-8; author reply e589-90. doi: 10.1200/JCO.2010.30.5466. Epub 2010 Aug 9. No abstract available.

PMID:
20697086
40.

Role of fusion subtype in Ewing sarcoma.

Barr FG, Meyer WH.

J Clin Oncol. 2010 Apr 20;28(12):1973-4. doi: 10.1200/JCO.2009.27.2161. Epub 2010 Mar 22. No abstract available.

PMID:
20308653
41.

Overlapping and distinct role of CXCR7-SDF-1/ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomas.

Grymula K, Tarnowski M, Wysoczynski M, Drukala J, Barr FG, Ratajczak J, Kucia M, Ratajczak MZ.

Int J Cancer. 2010 Dec 1;127(11):2554-68. doi: 10.1002/ijc.25245.

42.

Regulation of expression of stromal-derived factor-1 receptors: CXCR4 and CXCR7 in human rhabdomyosarcomas.

Tarnowski M, Grymula K, Reca R, Jankowski K, Maksym R, Tarnowska J, Przybylski G, Barr FG, Kucia M, Ratajczak MZ.

Mol Cancer Res. 2010 Jan;8(1):1-14. doi: 10.1158/1541-7786.MCR-09-0259. Epub 2010 Jan 12.

43.

High expression of the PAX3-FKHR oncoprotein is required to promote tumorigenesis of human myoblasts.

Xia SJ, Holder DD, Pawel BR, Zhang C, Barr FG.

Am J Pathol. 2009 Dec;175(6):2600-8. doi: 10.2353/ajpath.2009.090192. Epub 2009 Nov 5.

44.

Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group.

Barr FG, Duan F, Smith LM, Gustafson D, Pitts M, Hammond S, Gastier-Foster JM.

Genes Chromosomes Cancer. 2009 Aug;48(8):661-72. doi: 10.1002/gcc.20673.

45.

Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma.

Nishijo K, Chen QR, Zhang L, McCleish AT, Rodriguez A, Cho MJ, Prajapati SI, Gelfond JA, Chisholm GB, Michalek JE, Aronow BJ, Barr FG, Randall RL, Ladanyi M, Qualman SJ, Rubin BP, LeGallo RD, Wang C, Khan J, Keller C.

Cancer Res. 2009 Apr 1;69(7):2902-11. doi: 10.1158/0008-5472.CAN-08-3723.

46.

Embryonal and alveolar rhabdomyosarcoma of parameningeal sites in adults: a report of 13 cases.

Montone KT, Barr FG, Zhang PJ, Feldman MD, LiVolsi VA.

Int J Surg Pathol. 2009 Feb;17(1):22-30. doi: 10.1177/1066896908325876. Epub 2008 Oct 22.

PMID:
18945709
47.

ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status.

Corao DA, Biegel JA, Coffin CM, Barr FG, Wainwright LM, Ernst LM, Choi JK, Zhang PJ, Pawel BR.

Pediatr Dev Pathol. 2009 Jul-Aug;12(4):275-83. doi: 10.2350/08-03-0434.1.

PMID:
18788887
48.

Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target.

Mercado GE, Xia SJ, Zhang C, Ahn EH, Gustafson DM, Laé M, Ladanyi M, Barr FG.

Genes Chromosomes Cancer. 2008 Jun;47(6):510-20. doi: 10.1002/gcc.20554.

PMID:
18335505
49.

Molecular diagnosis of ewing family tumors: too many fusions... ?

Barr FG, Womer RB.

J Mol Diagn. 2007 Sep;9(4):437-40. Epub 2007 Jul 25. No abstract available.

50.

Correlation between histology and PAX/FKHR fusion status in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group.

Parham DM, Qualman SJ, Teot L, Barr FG, Morotti R, Sorensen PH, Triche TJ, Meyer WH; Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Am J Surg Pathol. 2007 Jun;31(6):895-901.

PMID:
17527077

Supplemental Content

Support Center